Chinese Biotech Initiative May Open Doors For U.S. Firms

Movement toward developing a robust, internationally active biotechnology industry is gaming momentum in the People’s Republic of China.. And as the movement picks up steam, one byproduct is an increasing number of stimulating opportunities for scientists and entrepreneurs connected with biotech firms outside of China. In an interview with The Scientist, Liu Yonghui, director of the National Center for Biotechnology Development in Beijing, said that his country wishes to “improve the

Written byAnne Moffat
| 6 min read

Register for free to listen to this article
Listen with Speechify
0:00
6:00
Share

Movement toward developing a robust, internationally active biotechnology industry is gaming momentum in the People’s Republic of China.. And as the movement picks up steam, one byproduct is an increasing number of stimulating opportunities for scientists and entrepreneurs connected with biotech firms outside of China. In an interview with The Scientist, Liu Yonghui, director of the National Center for Biotechnology Development in Beijing, said that his country wishes to “improve the quality of animals and plants through the creation of new varieties; to make new medicines and vaccines; and to build select areas of fundamental research, such as studies of protein structure and function.”

The products of such collaborations will be “mainly for [use in] China,” he says, adding that eventually, a thriving biotechnology industry could build export trade. As biotechnology gains familiarity and acceptance within China, observes Ezra Weisman, vice president for corporate development at New Brunswick Scientific, sales ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies